At Uromigos Live 2024, a bladder cancer panel moderated by Dr. Tom Powles focused on the use of antibody drug conjugates for the treatment of bladder cancer, analyzing the response rates of various ADC treatments and their related side effects. Dr. Powles was joined by Andrea Apolo, MD, of the National Institute of Health; Petros Grivas, MD, PhD, of the University of Washington; Shilpa Gupta, MD, of Cleveland Clinic; and Kala Sridhar, MD, of Princess Margaret Cancer Center. ...
Urothelial Carcinoma
Advertisement
Latest News
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
UGN-102 could become the first FDA-approved therapy for low-grade intermediate-risk non-muscle invasive bladder cancer.
The panelists wrap up this peri-operative therapy session with what the envision for the future for sparing bladders.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Part two features a discussion on the timing and rationale behind conducting trials for re-challenging patients.
The panelists discuss the use of immune checkpoint inhibitors and re-challenging patients with PD-1/PD-L1 therapies.
The panelists examine the existing data for T cell engagers in CRPC and how the data might affect clinical practice.
The panelists discuss T cell engagers, including an introduction and discussion of cytokine release syndrome.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
Advertisement
Advertisement
Latest News
Part two features a discussion on the timing and rationale behind conducting trials for re-challenging patients.
The panelists discuss the use of immune checkpoint inhibitors and re-challenging patients with PD-1/PD-L1 therapies.
The panelists examine the existing data for T cell engagers in CRPC and how the data might affect clinical practice.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.